Article Text

Download PDFPDF
Non-alcoholic fatty liver disease in patients with HCV genotype 4
  1. A El-Zayadi1,
  2. M Attia2,
  3. E M F Barakat3,
  4. K Zalata4,
  5. A Saeid5,
  6. H Hamdy6,
  7. A El-Nakeeb7
  1. 1Department of Tropical Medicine, Ain Shams University, Cairo and Cairo Liver Center, Giza, Egypt
  2. 2Department of Hepatology and Gastroenterology, Theodor Bilharz Research Institute, Cairo, Egypt
  3. 3Department of Tropical Medicine, Ain Shams University, Cairo, Egypt
  4. 4Department of Pathology, Mansoura University, Mansoura, Egypt
  5. 5Cairo Liver Center, Giza, Egypt
  6. 6Department of Tropical Medicine, Ain Shams University, Cairo, Egypt
  7. 7Cairo Liver Center, Giza, Egypt
  1. Correspondence to:
    Professor Abdel-Rahman El-Zayadi
    5 El-Gergawy St Dokki, Giza, Egypt; clcz{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hepatitis C infection is considered the leading cause of chronic liver disease in Egypt. Hepatitis C virus (HCV) genotype 4 is the predominant genotype in the Middle East including Egypt.1

A striking feature of HCV infection is its association with fat accumulation within hepatocytes,2 which is defined by the presence of hepatic steatosis with or without steatohepatitis.3 Hepatic steatosis has been reported in 30–70% of patients with HCV infection, even when the most common causes of steatosis are excluded.4 A causal relationship between infection with HCV genotype 3 and the incidence of hepatic steatosis has been elicited.5

In Egypt the true prevalence of non-alcoholic fatty liver disease is unknown among patients with HCV who are commonly infected with genotype 4. Our aim was to …

View Full Text


  • Competing interests: None.